Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Measles and rubella seroprevalence in a population of young adult blood donors, France 2013.

Antona D, Morel P, Jacquot C, Fonteneau L, Dina J, Vauloup-Fellous C, Gimeno L, Degeorges A, Gallian P, Lévy-Bruhl D.

Epidemiol Infect. 2019 Jan;147:e109. doi: 10.1017/S0950268819000050.

2.

Incidence of H1N1 2009 virus infection through the analysis of paired plasma specimens among blood donors, France.

Bone A, Guthmann JP, Assal A, Rousset D, Degeorges A, Morel P, Valette M, Enouf V, Jacquot E, Pelletier B, Le Strat Y, Pillonel J, Fonteneau L, van der Werf S, Lina B, Tiberghien P, Lévy-Bruhl D.

PLoS One. 2012;7(3):e33056. doi: 10.1371/journal.pone.0033056. Epub 2012 Mar 22.

3.

Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).

Beau-Faller M, Degeorges A, Rolland E, Mounawar M, Antoine M, Poulot V, Mauguen A, Barbu V, Coulet F, Prétet JL, Bièche I, Blons H, Boyer JC, Buisine MP, de Fraipont F, Lizard S, Olschwang S, Saulnier P, Prunier-Mirebeau D, Richard N, Danel C, Brambilla E, Chouaid C, Zalcman G, Hainaut P, Michiels S, Cadranel J.

J Thorac Oncol. 2011 Jun;6(6):1006-15. doi: 10.1097/JTO.0b013e318211dcee.

4.

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients.

Etienne-Grimaldi MC, Formento P, Degeorges A, Pierga JY, Delva R, Pivot X, Dalenc F, Espié M, Veyret C, Formento JL, Francoual M, Piutti M, de Crémoux P, Milano G.

Br J Clin Pharmacol. 2011 Jun;71(6):921-8. doi: 10.1111/j.1365-2125.2010.03896.x.

5.

Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis.

Mariani P, Lae M, Degeorges A, Cacheux W, Lappartient E, Margogne A, Pierga JY, Girre V, Mignot L, Falcou MC, Salmon RJ, Delattre O, De Cremoux P.

Anticancer Res. 2010 Oct;30(10):4229-35.

PMID:
21036746
6.

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.

Bidard FC, Mathiot C, Degeorges A, Etienne-Grimaldi MC, Delva R, Pivot X, Veyret C, Bergougnoux L, de Cremoux P, Milano G, Pierga JY.

Ann Oncol. 2010 Sep;21(9):1765-71. doi: 10.1093/annonc/mdq052. Epub 2010 Mar 16.

PMID:
20233745
7.

Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment.

Bollet MA, Savignoni A, De Koning L, Tran-Perennou C, Barbaroux C, Degeorges A, Sigal-Zafrani B, Almouzni G, Cottu P, Salmon R, Servant N, Fourquet A, de Cremoux P.

Breast Cancer Res. 2009;11(4):R54. doi: 10.1186/bcr2343. Epub 2009 Jul 28.

8.

Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.

De Cremoux P, Grandin L, Diéras V, Savignoni A, Degeorges A, Salmon R, Bollet MA, Reyal F, Sigal-Zafrani B, Vincent-Salomon A, Sastre-Garau X, Magdelénat H, Mignot L, Fourquet A; Breast Cancer Study Group of the Institut Curie.

Anticancer Res. 2009 May;29(5):1475-82.

9.

[Circulating tumor cells and breast cancer: detection techniques and clinical results].

Bidard FC, Saliba AE, Saias L, Degeorges A, Cremoux Pd, Viovy JL, Vincent-Salomon A, Mathiot C, Pierga JY, de Gramont A.

Bull Cancer. 2009 Jan;96(1):73-86. doi: 10.1684/bdc.2008.0797. Review. French.

10.

A new model of patient tumor-derived breast cancer xenografts for preclinical assays.

Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Diéras V, Poupon MF.

Clin Cancer Res. 2007 Jul 1;13(13):3989-98.

11.

[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].

Dieras V, Vincent-Salomon A, Degeorges A, Beuzeboc P, Mignot L, de Cremoux P.

Bull Cancer. 2007 Mar;94(3):259-66. Review. French.

12.

Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.

Colombel M, Filleur S, Fournier P, Merle C, Guglielmi J, Courtin A, Degeorges A, Serre CM, Bouvier R, Clézardin P, Cabon F.

Cancer Res. 2005 Jan 1;65(1):300-8.

13.

In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects.

Filleur S, Volpert OV, Degeorges A, Voland C, Reiher F, Clézardin P, Bouck N, Cabon F.

Genes Dev. 2001 Jun 1;15(11):1373-82.

14.

LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.

Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW.

Prostate. 2000 Jul 1;44(2):91-103 Jul 1;44(2).

PMID:
10881018
15.

Distribution of IGFBP-rP1 in normal human tissues.

Degeorges A, Wang F, Frierson HF Jr, Seth A, Sikes RA.

J Histochem Cytochem. 2000 Jun;48(6):747-54.

PMID:
10820148
16.

Loss of heterozygosity and lack of mutations of the XPG/ERCC5 DNA repair gene at 13q33 in prostate cancer.

Hyytinen ER, Frierson HF Jr, Sipe TW, Li CL, Degeorges A, Sikes RA, Chung LW, Dong JT.

Prostate. 1999 Nov 1;41(3):190-5.

PMID:
10517877
17.

Human prostate cancer expresses the low affinity insulin-like growth factor binding protein IGFBP-rP1.

Degeorges A, Wang F, Frierson HF Jr, Seth A, Chung LW, Sikes RA.

Cancer Res. 1999 Jun 15;59(12):2787-90.

18.

The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun.

Dejong V, Degeorges A, Filleur S, Ait-Si-Ali S, Mettouchi A, Bornstein P, Binétruy B, Cabon F.

Oncogene. 1999 May 20;18(20):3143-51.

19.

Role of epidermal-growth-factor receptor in tumor progression in transformed human mammary epithelial cells.

Ma L, Gauvillé C, Berthois Y, Degeorges A, Millot G, Martin PM, Calvo F.

Int J Cancer. 1998 Sep 25;78(1):112-9.

20.

Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?

Degeorges A, de Roquancourt A, Extra JM, Espie M, Bourstyn E, de Cremoux P, Soussi T, Marty M.

Breast Cancer Res Treat. 1998 Jan;47(1):47-55.

PMID:
9493975
21.

Effect of stromal and epithelial cells derived from normal and tumorous breast tissue on the proliferation of human breast cancer cell lines in co-culture.

Dong-Le Bourhis X, Berthois Y, Millot G, Degeorges A, Sylvi M, Martin PM, Calvo F.

Int J Cancer. 1997 Mar 28;71(1):42-8.

22.

The somatostatin receptor subtype 2 is expressed in normal and tumoral human tissues70.

Prévost G, Benamouzig R, Veber N, Fajac A, Tatoud R, Degeorges A, Eden P.

Cancer Detect Prev. 1997;21(1):62-70.

PMID:
9043765
23.

Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6.

Degeorges A, Tatoud R, Fauvel-Lafeve F, Podgorniak MP, Millot G, de Cremoux P, Calvo F.

Int J Cancer. 1996 Oct 9;68(2):207-14.

24.

Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adriamycin and taxol by the K562 leukemia cell line.

Le Moyec L, Tatoud R, Degeorges A, Calabresse C, Bauza G, Eugène M, Calvo F.

Cancer Res. 1996 Aug 1;56(15):3461-7.

25.

[2D and 3D reconstructionS after spiral x-ray computed tomographic acquisition. (2)].

Martin G, Degeorges A, Chameroy O, Villemot D, Souyet N, Rlvoire JM, Truong P.

J Radiol. 1996 May;77(5):373-81. French. No abstract available.

PMID:
8762937
26.

[2D and 3D reconstructions after spiral x-ray computed tomographic acquisition].

Martin G, Degeorges A, Chameroy O, Villemot D, Soyet N, Rlvoire JM, Truong P.

J Radiol. 1996 Apr;77(4):297-301. French. No abstract available.

PMID:
8734214
27.

Somatostatin receptors in prostate tissues and derived cell cultures, and the in vitro growth inhibitory effect of BIM-23014 analog.

Tatoud R, Degeorges A, Prévost G, Hoepffner JL, Gauvillé C, Millot G, Thomas F, Calvo F.

Mol Cell Endocrinol. 1995 Sep 22;113(2):195-204.

PMID:
8674827
28.
29.
30.

[Peptide growth factors in the prostate].

Tatoud R, Desgrandchamps F, DeGeorges A, Thomas F.

Pathol Biol (Paris). 1993 Oct;41(8):731-40. Review. French.

PMID:
7507232
31.

Single-steep transformation of human breast epithelial cells by SV40 large T oncogene.

Berthon P, Goubin G, Dutrillaux B, Degeorges A, Faille A, Gespach C, Calvo F.

Int J Cancer. 1992 Aug 19;52(1):92-7.

PMID:
1323542
32.

[MRI study of parathyroid adenoma. Value of T2-weighted sequences].

Brulé JM, Degeorges A, Mauss Y, Jost JB, Wenger JJ, Le Bras Y, Scheiber C, Marescaux J, Chambron J.

Ann Radiol (Paris). 1989;32(6):457-66. French.

PMID:
2699210
33.

[Echographic aspects of Crohn's disease. Apropos of 42 studies].

Schmutz G, Drape JL, Benhaim M, Jahn C, Chapuis A, Degeorges A.

J Radiol. 1986 Oct;67(10):697-706. French.

PMID:
3540288

Supplemental Content

Loading ...
Support Center